AxoGen, Inc.

AXGN

US05463X1063

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
7 ^USD	+2.79%		-8.38%	+2.49%

05-28	Axogen, Inc. Announces the Opening of its Axogen Processing Center	CI
05-16	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft	MT

AxoGen, Inc Promotes Dr. Angelo Scopelianos' as Chief Research and Development Officer

January 06, 2021 at 05:22 pm

AxoGen, Inc. promoted Dr. Angelo Scopelianos' as a Chief Research and Development Officer.

Latest news about AxoGen, Inc.

Axogen, Inc. Announces the Opening of its Axogen Processing Center	05-28	CI
AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft	05-16	MT
Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M	05-02	MT
AxoGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Axogen, Inc. Provides Revenue Guidance for the Year 2024	05-02	CI
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix	04-29	CI
Axogen Insider Sold Shares Worth $319,891, According to a Recent SEC Filing	03-08	MT
AxoGen, Inc. Announces Executive Changes	03-08	CI
AxoGen Files $100 Million Mixed-Securities Shelf	03-06	MT
Health Care Down After Mixed Earnings -- Health Care Roundup	03-05	DJ
Transcript : AxoGen, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
AxoGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024	03-05	CI
North American Morning Briefing : S&P 500 Futures -2-	03-05	DJ
AxoGen Says Trial of Axoguard Nerve Cap Met Primary Endpoint of Pain Reduction	01-19	MT
Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study	01-18	CI
Axogen Expects Higher Q4 Revenue; CEO Plans to Retire	01-04	MT
AxoGen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023	01-04	CI
AxoGen, Inc. Revises Revenue Guidance for the Full Year of 2023	01-04	CI
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025	01-04	CI
Axogen, Inc. Announces Plans to Retirement of Karen Zaderej as President, Effective January 2025	01-04	CI
AxoGen, Inc. Announces Executive Changes	01-04	CI
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors	12-26	CI
AxoGen, Inc. Announces CFO Changes	12-06	CI

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AxoGen, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7 USD

Average target price

13.4 USD

Spread / Average Target

+91.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AXOGEN, INC.	+2.49%	306M
THERMO FISHER SCIENTIFIC	+6.37%	216B
DANAHER CORPORATION	+10.21%	189B
INTUITIVE SURGICAL, INC.	+28.22%	153B
BOSTON SCIENTIFIC CORPORATION	+34.42%	114B
EDWARDS LIFESCIENCES CORPORATION	+19.21%	54.78B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.13%	48.47B
AGILENT TECHNOLOGIES, INC.	-4.16%	38.88B
GE HEALTHCARE TECHNOLOGIES INC.	+2.39%	36.14B
RESMED, INC.	+19.65%	30.23B

Other Advanced Medical Equipment & Technology

AxoGen, Inc.

Equities

AXGN

US05463X1063

Advanced Medical Equipment & Technology

AxoGen, Inc Promotes Dr. Angelo Scopelianos' as Chief Research and Development Officer

Latest news about AxoGen, Inc.

Chart AxoGen, Inc.

Company Profile

Income Statement Evolution

Ratings for AxoGen, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology